Tevogen Bio Holdings Inc. (TVGNW) Analyse boursière

Présentation de l'entreprise

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company dedicated to developing off-the-shelf, precision T cell therapies designed for the treatment of infectious diseases, cancers, and various other disorders. The entity functions within the biotechnology and pharmaceutical sectors, specifically focusing on the advancement of novel therapeutic candidates like TVGN 489, which has successfully completed its Phase 1 clinical trial for the treatment of ambulant patients. The company's operational scale is defined by a market capitalization and annual revenue that are not publicly disclosed in the current financial data, alongside a workforce comprising 18 employees. This specific employee count and the lack of disclosed revenue figures indicate that Tevogen Bio is an early-stage biotechnology firm where value is primarily derived from intellectual property and clinical pipeline progress rather than established commercial sales or large-scale manufacturing operations.

Santé financière

The company reports a net income for the trailing twelve months of $-26,825,432 and an EBITDA of $-25,949,942, while revenue and sales figures remain unquantified in the available data. The significant negative net income relative to the reported EBITDA suggests that the company incurs substantial non-operating expenses, interest costs, or one-time charges that are not captured in the EBITDA metric, highlighting a cost structure heavily weighted toward research and development and administrative overheads rather than production costs. Free cash flow stands at $-1,774,858, indicating that the company is currently burning cash to fund its clinical trials and development activities, which limits immediate financial flexibility and reliance on external capital sources. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure common for pre-revenue biotechnology companies where no commercial sales have yet generated profitability. The balance sheet shows cash holdings of $552,372 against total debt of $7.50M, resulting in a negative debt-to-equity situation that reflects a leveraged position relative to its limited liquid assets. The current ratio is 0.22, which signals a severe liquidity constraint where current liabilities significantly exceed current assets, posing a risk of short-term solvency challenges. Furthermore, the return on equity and return on assets are reported as -416.5%, revealing that management is currently destroying shareholder value and utilizing assets inefficiently due to the absence of revenue generation.

Évaluation de la valorisation

Trailing P/E, forward P/E, and price-to-sales ratios are not applicable for Tevogen Bio Holdings Inc. given the company's lack of positive earnings and disclosed sales data, implying that traditional valuation multiples cannot be used to assess its current market standing. The price-to-book ratio is listed at -0.01, a negative figure that mathematically indicates the market values the company's equity below its book value, often seen in distressed or pre-profitability scenarios where assets may not reflect true future potential. The EV/EBITDA multiple is also not applicable, reinforcing that the firm is not yet profitable enough to be valued on cash-flow generation metrics. The stock's 52-week trading range is confined between a high of $0.03 and a low of $0.03, meaning the current price is trading exactly at the boundary of this historical range with no intrayear volatility. The beta value is recorded as -0.30, an anomalous metric for equities that suggests an inverse correlation to the broader market, though such a value often indicates data irregularities or extreme idiosyncratic risk in small-cap biotechnology stocks.

Growth & Income

Revenue growth and earnings growth rates are not available in the provided financial statements, preventing a direct comparison of earnings velocity relative to sales expansion. The company does not distribute a dividend, evidenced by a missing dividend yield and payout ratio, as it prioritizes the reinvestment of all available capital into its clinical pipeline and drug development efforts rather than returning cash to shareholders. This absence of dividend payments is typical for clinical-stage immunotherapy companies that must allocate scarce resources toward advancing candidates like TVGN 489 through later-stage trials. Consequently, the overall growth and income profile of Tevogen Bio Holdings Inc. is characterized by a total reliance on capital appreciation potential rather than income generation, with growth metrics remaining undefined until commercialization milestones are achieved.